PASADENA, Calif.--(BUSINESS WIRE)--Calhoun Vision, the developer of groundbreaking ocular technology designed to allow cataract surgeons to adjust the power of a lens after implantation in the eye, has announced enrollment of the 300th patient in the Phase III clinical study of its Light Adjustable Lens (LAL®). The study, which is being conducted at 18 centers across the country, will include a total of 600 patients, with 400 implanted with the LAL and 200 implanted with a monofocal control lens of the surgeon’s choosing. Unlike traditional intraocular lenses, which are made of non-adjustable material, the LAL technology is designed to allow surgeons for the first time to change and customize the power of the lens after it has been implanted in the eye.
Help employers find you! Check out all the jobs and post your resume.
